Eledon’s Antibody, Tegoprubart, Shows Promise in ALS Phase 2 Trial
Eledon Pharmaceuticals’ investigational antibody-based therapy, tegoprubart, safely and effectively reduces levels of inflammatory biomarkers in adults with…
Articles by Marta Figueiredo, PhD
Masitinib Being Reviewed for OK in Canada as Add-on ALS Therapy
Health Canada has started to review AB Science’s application requesting that masitinib be approved as an add-on therapy for…
World-renowned ALS Researcher, Clinician to Receive MDA Award
Stanley H. Appel, a world-renowned expert in amyotrophic lateral sclerosis (ALS) and the founder of the first multidisciplinary clinic…
Radicava Oral Suspension Earns FDA Approval
The U.S. Food and Drug Administration (FDA) has approved Mitsubishi Tanabe Pharma America (MTPA)’s oral suspension formulation of edaravone,…
Patient Dosing Starts in Phase 2 Clinical Trial of Oral SAR443820
A Phase 2 clinical trial has begun dosing patients to evaluate the safety and effectiveness of Denali Therapeutics‘ investigational…
Online Survey to Assess Stigma’s Impact in ALS Patients, Caregivers
An international team of researchers is asking adults with amyotrophic lateral sclerosis (ALS) and their family caregivers to complete…
#AAN2022 – How Environmental Exposure Affects ALS Risk Is Studied
Researchers at the University of Michigan are focused on establishing cause and effect relationships between environmental and occupational exposures with…
Aclipse Will Use $1.4M DOD Grant to Advance M102 to Clinical Trials
The U.S. Department of Defense (DOD) has awarded a $1.475 million grant to Aclipse Therapeutics to advance M102 —…
Biogen, Ionis Stopping BIIB078 Development Due to Lack of Benefit
Based on data from a Phase 1 clinical trial, Biogen and Ionis Pharmaceuticals are discontinuing development of BIIB078,…
#AAN2022 – US Real-world Data Show Radicava Boosts Survival Rate
Treatment with Radicava (edaravone) for at least one year significantly reduces the risk of death in people with amyotrophic…